Media Contact: Stephanie Bulak email@example.com
On February 25, 2015, The U.S. Food and Drug Administration approved Avycaz (ceftazidime-avibactam) to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.Avycazis a fixed-combination drug containing ceftazidime and avibactam, a new beta-lactamase inhibitor.
See http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm for more info.
An advisory committee to the US Food and Drug Administration (FDA) voted unanimously to recommend isavuconazonium (ISA) (Cresemba, Astellas Pharma, Inc) for the treatment of adults with invasive aspergillosis (IA) and voted (8 yes, 2 no, 1 abstain) to recommend the drug for the treatment of adults with invasive mucormycosis (IM).http://www.medscape.com/viewarticle/838620
January 8, 2015 4pm ET/1pm PT Cultivating Health January 8, 2015 4pm ET/1pm PT Our gut bacteria shape our health. Dr. Martin Blaser, past president of the Infectious Diseases Society of America (IDSA), explains the connection highlighted in his recent book, Missing Microbes: How the Overuse of Antibiotics is Fueling Our Modern Plagues. Dr. Lance Price, microbiologist and public health professor at George Washington University, explores the contribution of industrial meat production, including its reliance on antibiotics. John Billington, Director of Health Policy at the Infectious Diseases Society of America, will discuss the latest antibiotics policy issues. IDSA cosponsors.
Register at : https://attendee.gotowebinar.com/register/6416201563699806977
For those that may wear an Infection Control hat or want to buff up on rapid diagnostics, a webinar is being offered at 1p (EST). Registration is available at this site. Details below:
Date: Wednesday, December 10, 2014
Time: 1:00–2:00 PM Eastern (US) Time
Reducing healthcare–associated infections requires an integrated effort from all staff responsible for patient care, including laboratorians. This presentation will discuss the laboratory’s critical role in this endeavor, as well as important diagnostic tests that can facilitate infection control decisions.
At the end of this program, participants will be able to:
First came the wave of new agents aimed at resistant gram positive organisms, now the first novel serine beta-lactam/beta lactamase combination with expanded activity against multidrug resistant gram negative agents.The Anti-Infective Drug Advisory Committee (AIDAC) Meeting meets December 5, 2014 to discuss the new drug application (NDA) for ceftazidime-avibactam, submitted by Cerexa Inc., for the proposed indications of: Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, including Acute Pyelonephritis and Limited Use Indication: Aerobic Gram-negative Infections with Limited Treatment Options.
This year, Get Smart About Antibiotics Week is being observed during November 17–23, 2014. This is an annual observance to raise awareness of the threat of antibiotic resistance and the importance of appropriate prescribing and use. The observance is a key component of CDC's efforts to improve antibiotic stewardship in communities, in health care facilities, and on farms in collaboration with state-based programs and others. Get Smart About Antibiotics Week coincides with many global antibiotic resistance observances, including those in Europe, Australia, and Canada. Information on scheduled activities and how to get involved in combating antibiotic resistance is available at http://www.cdc.gov/getsmart/week.
For those who work in acute care hospitals, given the recent events in Dallas, TX, would encourage review of the CDC website for the latest and most reliable information on Ebola virus and the response needed at the local level particularly at referral centers. There are also links to the potential for IND use of ZMapp. The CDC’s Clinician Outreach and Communication Activity (COCA) program continues to organize webinars. The American Hospital Association will be conducting a webinar program tomorrow October 17th at 11am EST,
The U.S. Food and Drug Administration approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. It is the first approved regimen that is interferon or ribavirin sparing.
For more information, please visit: Harvoni.
Society of Infectious Diseases Pharmacists • 121 W. State Street, Geneva, IL 60134
630-318-3291 • firstname.lastname@example.org
Proudly Managed by Affinity Strategies